OpenURL Connection Search

Select item for more details and to access through your institution.

Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263230
By:
- Delpassand, Ebrahim S.;
- Tworowska, Izabela;
- Esfandiari, Rouzbeh;
- Torgue, Julien;
- Hurt, Jason;
- Shafie, Afshin;
- Núñez, Rodolfo
Publication type:
Article
Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTRExpressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263230
By:
- Delpassand, Ebrahim S.;
- Tworowska, Izabela;
- Esfandiari, Rouzbeh;
- Torgue, Julien;
- Hurt, Jason;
- Shafie, Afshin;
- Núñez, Rodolfo
Publication type:
Article
Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR)Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263230
By:
- Delpassand, Ebrahim S.;
- Tworowska, Izabela;
- Esfandiari, Rouzbeh;
- Torgue, Julien;
- Hurt, Jason;
- Shafie, Afshin;
- Núñez, Rodolfo
Publication type:
Article
Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.263230
By:
- Delpassand, Ebrahim S.;
- Tworowska, Izabela;
- Esfandiari, Rouzbeh;
- Torgue, Julien;
- Hurt, Jason;
- Shafie, Afshin;
- Núñez, Rodolfo
Publication type:
Article
Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTRExpressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.263230
By:
- Delpassand, Ebrahim S.;
- Tworowska, Izabela;
- Esfandiari, Rouzbeh;
- Torgue, Julien;
- Hurt, Jason;
- Shafie, Afshin;
- Núñez, Rodolfo
Publication type:
Article
Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTRExpressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 3, p. 1, doi. 10.2967/jnumed.121.263230
By:
- Delpassand, Ebrahim S.;
- Tworowska, Izabela;
- Esfandiari, Rouzbeh;
- Torgue, Julien;
- Hurt, Jason;
- Shafie, Afshin;
- Núñez, Rodolfo
Publication type:
Article
Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263230
By:
- Delpassand, Ebrahim S.;
- Tworowska, Izabela;
- Esfandiari, Rouzbeh;
- Torgue, Julien;
- Hurt, Jason;
- Shafie, Afshin;
- Núñez, Rodolfo
Publication type:
Article
Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 1, p. 1, doi. 10.2967/jnumed.121.263230
By:
- Delpassand, Ebrahim S.;
- Tworowska, Izabela;
- Esfandiari, Rouzbeh;
- Torgue, Julien;
- Hurt, Jason;
- Shafie, Afshin;
- Núñez, Rodolfo
Publication type:
Article
Safety of PSMA-targeted molecular radioligand therapy with 177Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262543
By:
- Calais, Jeremie;
- Czernin, Johannes;
- Thin, Pan;
- Gartmann, Jeannine;
- Nguyen, Kathleen;
- Armstrong, Wesley R;
- Allen-Auerbach, Martin;
- Quon, Andrew;
- Bahri, Shadfar;
- Gupta, Pawan 5;
- Gardner, Linda;
- Dahlbom, Magnus;
- He, Beilei;
- Esfandiari, Rouzbeh;
- Ranganathan, David;
- Herrmann, Ken;
- Eiber, Matthias;
- Fendler, Wolfgang P.;
- Delpassand, Ebrahim
Publication type:
Article
Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality?
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.261906
By:
- Gafita, Andrei;
- Hui Wang;
- Robertson, Andrew;
- Armstrong, Wesley R.;
- Zaum, Raphael;
- Weber, Manuel;
- Yagubbayli, Farid;
- Kratochwil, Clemens;
- Grogan, Tristan R.;
- Nguyen, Kathleen;
- Navarro, Fernando;
- Esfandiari, Rouzbeh;
- Rauscher, Isabel;
- Menze, Bjoern;
- Elashoff, David;
- Delpassand, Ebrahim S.;
- Herrmann, Ken;
- Czernin, Johannes;
- Hofman, Michael S.;
- Calais, Jeremie
Publication type:
Article
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu- PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.261982
By:
- Calais, Jeremie;
- Gafita, Andrei;
- Eiber, Matthias;
- Armstrong, Wesley R.;
- Gartmann, Jeannine;
- Thin, Pan;
- Nguyen, Kathleen;
- Lok, Vincent;
- Gosa, Laura;
- Grogan, Tristan;
- Esfandiari, Rouzbeh;
- Allen-Auerbach, Martin;
- Quon, Andrew;
- Bahri, Shadfar;
- Gupta, Pawan;
- Gardner, Linda;
- Ranganathan, David;
- Slavik, Roger;
- Dahlbom, Magnus;
- Herrmann, Ken
Publication type:
Article
Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality?
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.261906
By:
- Gafita, Andrei;
- Hui Wang;
- Robertson, Andrew;
- Armstrong, Wesley R.;
- Zaum, Raphael;
- Weber, Manuel;
- Yagubbayli, Farid;
- Kratochwil, Clemens;
- Grogan, Tristan R.;
- Nguyen, Kathleen;
- Navarro, Fernando;
- Esfandiari, Rouzbeh;
- Rauscher, Isabel;
- Menze, Bjoern;
- Elashoff, David;
- Delpassand, Ebrahim S.;
- Herrmann, Ken;
- Czernin, Johannes;
- Hofman, Michael S.;
- Calais, Jeremie
Publication type:
Article
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.261982
By:
- Calais, Jeremie;
- Gafita, Andrei;
- Eiber, Matthias;
- Armstrong, Wesley R;
- Gartmann, Jeannine;
- Thin, Pan;
- Nguyen, Kathleen;
- Lok, Vincent;
- Gosa, Laura;
- Grogan, Tristan;
- Esfandiari, Rouzbeh;
- Allen-Auerbach, Martin;
- Quon, Andrew;
- Bahri, Shadfar;
- Gupta, Pawan;
- Gardner, Linda;
- Ranganathan, David;
- Slavik, Roger;
- Dahlbom, Magnus;
- Herrmann, Ken
Publication type:
Article
Safety of PSMA-targeted molecular radioligand therapy with 177Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262543
By:
- Calais, Jeremie;
- Czernin, Johannes;
- Thin, Pan;
- Gartmann, Jeannine;
- Nguyen, Kathleen;
- Armstrong, Wesley R.;
- Allen-Auerbach, Martin;
- Quon, Andrew;
- Bahri, Shadfar;
- Gupta, Pawan;
- Gardner, Linda;
- Dahlbom, Magnus;
- Beilei He;
- Esfandiari, Rouzbeh;
- Ranganathan, David;
- Herrmann, Ken;
- Eiber, Matthias;
- Fendler, Wolfgang P.;
- Delpassand, Ebrahim
Publication type:
Article
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177LuPSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.261982
By:
- Calais, Jeremie;
- Gafita, Andrei;
- Eiber, Matthias;
- Armstrong, Wesley R.;
- Gartmann, Jeannine;
- Thin, Pan;
- Nguyen, Kathleen;
- Lok, Vincent;
- Gosa, Laura;
- Grogan, Tristan;
- Esfandiari, Rouzbeh;
- Allen-Auerbach, Martin;
- Quon, Andrew;
- Bahri, Shadfar;
- Gupta, Pawan;
- Gardner, Linda;
- Ranganathan, David;
- Slavik, Roger;
- Dahlbom, Magnus;
- Herrmann, Ken
Publication type:
Article
Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality?
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.261906
By:
- Gafita, Andrei;
- Hui Wang;
- Robertson, Andrew;
- Armstrong, Wesley R.;
- Zaum, Raphael;
- Weber, Manuel;
- Yagubbayli, Farid;
- Kratochwil, Clemens;
- Grogan, Tristan R.;
- Nguyen, Kathleen;
- Navarro, Fernando;
- Esfandiari, Rouzbeh;
- Rauscher, Isabel;
- Menze, Bjoern;
- Elashoff, David;
- Delpassand, Ebrahim S.;
- Herrmann, Ken;
- Czernin, Johannes;
- Hofman, Michael S.;
- Calais, Jeremie
Publication type:
Article
Safety of PSMA-targeted molecular radioligand therapy with 177Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262543
By:
- Calais, Jeremie;
- Czernin, Johannes;
- Thin, Pan;
- Gartmann, Jeannine;
- Nguyen, Kathleen;
- Armstrong, Wesley R.;
- Allen-Auerbach, Martin;
- Quon, Andrew;
- Bahri, Shadfar;
- Gupta, Pawan;
- Gardner, Linda;
- Dahlbom, Magnus;
- Beilei He;
- Esfandiari, Rouzbeh;
- Ranganathan, David;
- Herrmann, Ken;
- Eiber, Matthias;
- Fendler, Wolfgang P.;
- Delpassand, Ebrahim
Publication type:
Article
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.261982
By:
- Calais, Jeremie;
- Gafita, Andrei;
- Eiber, Matthias;
- Armstrong, Wesley R.;
- Gartmann, Jeannine;
- Thin, Pan;
- Nguyen, Kathleen;
- Lok, Vincent;
- Gosa, Laura;
- Grogan, Tristan;
- Esfandiari, Rouzbeh;
- Allen-Auerbach, Martin;
- Quon, Andrew;
- Bahri, Shadfar;
- Gupta, Pawan;
- Gardner, Linda;
- Ranganathan, David;
- Slavik, Roger;
- Dahlbom, Magnus;
- Herrmann, Ken
Publication type:
Article
Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality?
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.261906
By:
- Gafita, Andrei;
- Hui Wang;
- Robertson, Andrew;
- Armstrong, Wesley R.;
- Zaum, Raphael;
- Weber, Manuel;
- Yagubbayli, Farid;
- Kratochwil, Clemens;
- Grogan, Tristan R.;
- Nguyen, Kathleen;
- Navarro, Fernando;
- Esfandiari, Rouzbeh;
- Rauscher, Isabel;
- Menze, Bjoern;
- Elashoff, David;
- Delpassand, Ebrahim S.;
- Herrmann, Ken;
- Czernin, Johannes;
- Hofman, Michael S.;
- Calais, Jeremie
Publication type:
Article
Safety of PSMA-targeted molecular radioligand therapy with 177Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.262543
By:
- Calais, Jeremie;
- Czernin, Johannes;
- Thin, Pan;
- Gartmann, Jeannine;
- Nguyen, Kathleen;
- Armstrong, Wesley R.;
- Allen-Auerbach, Martin;
- Quon, Andrew;
- Bahri, Shadfar;
- Gupta, Pawan;
- Gardner, Linda;
- Dahlbom, Magnus;
- Beilei He;
- Esfandiari, Rouzbeh;
- Ranganathan, David;
- Herrmann, Ken;
- Eiber, Matthias;
- Fendler, Wolfgang P.;
- Delpassand, Ebrahim
Publication type:
Article
Prospective phase 2 trial o _PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.261982
By:
- Calais, Jeremie;
- Gafita, Andrei;
- Eiber, Matthias;
- Armstrong, Wesley R.;
- Gartmann, Jeannine;
- Pan Thin;
- Nguyen, Kathleen;
- Lok, Vincent;
- Gosa, Laura;
- Grogan, Tristan;
- Esfandiari, Rouzbeh;
- Allen-Auerbach, Martin;
- Quon, Andrew;
- Bahri, Shadfar;
- Gupta, Pawan;
- Gardner, Linda;
- Ranganathan, David;
- Slavik, Roger;
- Dahlbom, Magnus;
- Herrmann, Ken
Publication type:
Article
Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality?
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.261906
By:
- Gafita, Andrei;
- Hui Wang;
- Robertson, Andrew;
- Armstrong, Wesley R.;
- Zaum, Raphael;
- Weber, Manuel;
- Yagubbayli, Farid;
- Kratochwil, Clemens;
- Grogan, Tristan R.;
- Nguyen, Kathleen;
- Navarro, Fernando;
- Esfandiari, Rouzbeh;
- Rauscher, Isabel;
- Menze, Bjoern;
- Elashoff, David;
- Delpassand, Ebrahim S.;
- Herrmann, Ken;
- Czernin, Johannes;
- Hofman, Michael S.;
- Calais, Jeremie
Publication type:
Article
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu- PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.121.261982
By:
- Calais, Jeremie;
- Gafita, Andrei;
- Eiber, Matthias;
- Armstrong, Wesley R.;
- Gartmann, Jeannine;
- Thin, Pan;
- Nguyen, Kathleen;
- Lok, Vincent;
- Gosa, Laura;
- Grogan, Tristan;
- Esfandiari, Rouzbeh;
- Allen-Auerbach, Martin;
- Quon, Andrew;
- Bahri, Shadfar;
- Gupta, Pawan;
- Gardner, Linda;
- Ranganathan, David;
- Slavik, Roger;
- Dahlbom, Magnus;
- Herrmann, Ken
Publication type:
Article
Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality?
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.121.261906
By:
- Gafita, Andrei;
- Wang, Hui;
- Robertson, Andrew;
- Armstrong, Wesley R.;
- Zaum, Raphael;
- Weber, Manuel;
- Yagubbayli, Farid;
- Kratochwil, Clemens;
- Grogan, Tristan R.;
- Nguyen, Kathleen;
- Navarro, Fernando;
- Esfandiari, Rouzbeh;
- Rauscher, Isabel;
- Menze, Bjoern;
- Elashoff, David;
- Delpassand, Ebrahim S.;
- Herrmann, Ken;
- Czernin, Johannes;
- Hofman, Michael S.;
- Calais, Jeremie
Publication type:
Article
Alpha‐emitter therapy for pediatric relapsed metastatic pancreatic neuroendocrine tumor.
Published in:
Pediatric Blood & Cancer, 2024, v. 71, n. 6, p. 1, doi. 10.1002/pbc.30961
By:
- Wahba, Andrew;
- Delpassand, Ebrahim S.;
- Nunez, Rodolfo;
- Esfandiari, Rouzbeh;
- Venkatramani, Rajkumar
Publication type:
Article

Found: 25

Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.

Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTRExpressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.

Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR)Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.

Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.

Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTRExpressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.

Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTRExpressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.

Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.

Targeted Alpha-Emitter Therapy With <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial.

Safety of PSMA-targeted molecular radioligand therapy with <sup>177</sup>Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312.

Tumor sink effect in 68Ga-PSMA-11 PET: Myth or Reality?

Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu- PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.

Tumor sink effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?

Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort.

Safety of PSMA-targeted molecular radioligand therapy with <sup>177</sup>Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312.

Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177LuPSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.

Tumor sink effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?

Safety of PSMA-targeted molecular radioligand therapy with <sup>177</sup>Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312.

Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.

Tumor sink effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?

Safety of PSMA-targeted molecular radioligand therapy with <sup>177</sup>Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312.

Prospective phase 2 trial o _PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.

Tumor sink effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?

Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu- PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.

Tumor sink effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?

Alpha‐emitter therapy for pediatric relapsed metastatic pancreatic neuroendocrine tumor.